SCIENCE@home

Engineering yeast for the production of breviscapine by genomic analysis and synthetic biology approaches

Xiaonan Liu,J. Cheng,Guanghui Zhang,Wentao Ding,Lijin Duan,Jing Yang,Ling Kui,Xiaozhi Cheng,Jiangxing Ruan,W. Fan,Junwen Chen,G. Long,Yan Zhao,Jing Cai,Wen Wang,Yanhe Ma,Yang Dong,Sheng-chao Yang,Huifeng Jiang

Published 2018 in Nature Communications

ABSTRACT

The flavonoid extract from Erigeron breviscapus, breviscapine, has increasingly been used to treat cardio- and cerebrovascular diseases in China for more than 30 years, and plant supply of E. breviscapus is becoming insufficient to satisfy the growing market demand. Here we report an alternative strategy for the supply of breviscapine by building a yeast cell factory using synthetic biology. We identify two key enzymes in the biosynthetic pathway (flavonoid-7-O-glucuronosyltransferase and flavone-6-hydroxylase) from E. breviscapus genome and engineer yeast to produce breviscapine from glucose. After metabolic engineering and optimization of fed-batch fermentation, scutellarin and apigenin-7-O-glucuronide, two major active ingredients of breviscapine, reach to 108 and 185 mg l–1, respectively. Our study not only introduces an alternative source of these valuable compounds, but also provides an example of integrating genomics and synthetic biology knowledge for metabolic engineering of natural compounds. Breviscapine is the flavonoid extract from medical plant Erigeron breviscapus for the treatment of cardio- and cerebrovascular disease. Here, the authors identify the key enzymes of the biosynthetic pathway from the plant genome and engineer yeast to produce breviscapine from glucose.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-62 of 62 references · Page 1 of 1

CITED BY

Showing 1-100 of 206 citing papers · Page 1 of 3

123
Next